Статья
БЕЗОПАСНОСТЬ КАРДИОСЕЛЕКТИВНЫХ БЕТА-АДРЕНОБЛОКАТОРОВ ДЛЯ ЛЕЧЕНИЯ КАРДИОВАСКУЛЯРНОЙ ПАТОЛОГИИ У ПАЦИЕНТОВ С ХРОНИЧЕСКИМИ ОБСТРУКТИВНЫМИ ЗАБОЛЕВАНИЯМИ ЛЕГКИХ
Обзор посвящен проблеме использования кардиоселективных β-адреноблокаторов у пациентов с кардиоваскулярной патологией, сочетанной с хронической обструктивной болезнью легких (ХОБЛ). Приводятся данные мета- анализов, клинических исследований, обзоров, показавших безопасность назначения кардиоселективных β-адреноблокаторов у пациентов с ХОБЛ. Также затронуты проблемы общей и сердечно-сосудистой смертности у пациентов с ХОБЛ и влияние на нее использования кардиоселективных β-адреноблокаторов.
1. Авдеева Е.В., Ковальская Е.А., Вострикова О.Г. Факторы риска ИБС и показатели липидного обмена при кардиореспираторных заболеваниях //Клиническая медицина. – 2000. – № 3. – с. 25-28.
2. Долинская М.Г. Клинико-патогенетическая характеристика и лечение больных хроническим обструктивным бронхитом с сопутствующей ишемической болезнью сердца: Автореф. дис. канд. мед. наук. – Луганск, 1999.
3. Козлова Л.И., Бузунов Р. В., Чучалин А.Г. Пятнадцатилетний анализ особенностей ХОБЛ у больных ИБС //Терапевтический архив. – 2001. – № 3. – с. 33-37.
4. Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания //Пульмонология. – 2008. – N. 2. – c. 5-14.
5. Ablad B., Carlsson E., Dahlof C. Some sapects of the pharmacology of beta-adrenoreceptor blockers //Drugs. – 1976. – V.11(1). – pp. 100-111.
6. Anthonisen N. R., Connett J. E., Enright P. L. et al. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study //Am. J. Respir. Crit. Care. Med.– 2002. – V.166. – pp. 333–339.
7. Andrus M.R., Holloway K.P., Clark D. B. //Ann. Pharmacotherapy. – 2004. – V. 38. – pp. 142-145.
8. Buch P., Friberg J., Scharling H. et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study //Eur. Respir. J. – 2003. – V.21(6). – pp. 1012-1016.
9. Beumer H. M. Adverse effects of beta-adrenergic receptor blocker blocking drugs on respiratory function //Drugs. – 1974. – V.7 – pp. 130-138.
10. British guideline on the management of astma //Thorax. – 2003. – V.58(1). – pp. 1-94.
11. Cazzola M., Matera M.G. Beta- blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution //Am. J. Respir. Crit. Care. Med.– 2008; V.178. – pp. 661–662.
12. Chatterjee S.S. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics //J. Cardiovasc. Pharmacology. – 1986. – V.8. – pp. 74-77.
13. Donald B.H. Cardiovascular diseases in chronic obstructive pulmonary disease //Proceedings Am. Thoracic Society. – 2005. – V.2. – pp. 44-49.
14. Dorow P., Bethge H., Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non-asthmatic chronic obstructive lung disease and angina pectoris //Eur. J. Clin. Pharmacology. – 1986. – V.31. – pp. 143-147.
15. Expert consensus document on beta-adrenergyc receptor blockers. The Task Force on Beta- blockers of the European Society of Cardiology //Eur. Heart. J. – 2004. – V.25. – pp. 1341-1362.
16. Fogari R., Zoppi A., Tettamati F. et al. Comparative effects of celiprolol, propranolol, oxprenolol and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease //Cardiovasc.Drugs Ther. – 1990. – V.4. – pp. 1145-1150.
17. Formgren H. The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics //Br. J. Clin. Pharmacology. – 1976. – V.3. – pp. 1007-1014.
18. Fuso L., Incalzi R.A., Pistelli R. et al. Predicting mortality of patients for acutely exacerbated COPD //Am. J. Med. – 1995. – V. 98(3). – pp. 272-277.
19. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management and prevention of COPD. NHLBI/WHO workshop report. Last update 2006. www.goldcopd. org.
20. Hansell A. L., Walk J. A., Soriano J. B. What do COPD patients die from? A multiple cause coding analysis //Eur. Respir. J. – 2003. – V.22(5). – pp. 809-814.
21. Hole D. J., Watt G. C., Davey-Smith G. et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study //BMJ.– 1996. – V.313. – pp. 711–775.
22. Houman A., Andonis G. Beta- blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint //Prim. Care Respir. J. – 2005. – V.14(5). – pp. 236-241.
23. Kleiger R.E., Senior R.M. Long term electrocardiographic monitoring of ambulatory patients with COPD //Chest. – 1974. – V. 65. – pp. 483.
24. Lawrence D.S., Sahay J.N., Chatterjee S.S. et al. β-blockers in astma //Drugs. – 1983. – V.25 – pp. 232-236.
25. McGarvey L.P., John M., Anderson J.A. et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee //Thorax. – 2007. – V.62. – pp. 411- 415.
26. Menneke J., Johan Z., Dirkje S. et аl. Detrimental effects of betablockers in COPD. A concern for nonselective beta- blockers // CHEST. – 2005. – V.127. – pp. 818-824.
27. Prichard B.N., Gillam P.M. Treatment of hypertension with propranolol //Br. Med. J. – 1969. – V.1(5635). – pp. 7-16.
28. Salpeter S.R., Ormiston T.M., Salpeter E.E. et al. Cardioselective β-blockers for chronic obstructive pulmonary disease: a metaanalysis //Ann. Inter. Med. – 2002. – V.137 – pp. 715-725.
29. Salpeter S.R., Ormiston T.M., Salpeter E.E. et al. Cardioselective β-blockers for chronic obstructive pulmonary disease: a metaanalysis //Respir. Med. – 2003. – V.97(10). – pp. 1094-1101.
30. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardioselective betablockers for chronic obstructive pulmonary disease //Сochrane Datebase Syst. Rev. – 2005. – V.19(14). – CD003566.
31. Sidney S., Sorel M., Quesenberry C. et al. COPD and incident cardiovascular diseases hospitalizations and mortality: Kaiser Permanente Medical Care Program //CHEST. – 2005. – V. 128(4). – pp. 2068-2075.
32. Stephen I.R. Clinical approach to patients with chronic obstructive pulmonary disease and cardiovascular diseases //Proceedings Am. Thoracic Society. – 2005. – V.2 – pp. 94-100.
33. Yvette R.B.M. van Gestel, Sanne E. Hoeks, Don de Sin et al. Impact of cardioselective beta- blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis //Am. J. Respir. Crit. Care. Med.– 2008. – V.178. – pp. 698– 700.